The Alexander Laboratory's research focuses on understanding the fundamental mechanisms of amyloid formation and deposition in transthyretin amyloidosis (ATTR).
The Huang Lab’s research at Stanford focuses on the interactions between stem cells and the extracellular matrix microenvironment to engineer cardiovascular and musculoskeletal tissues for regenerative medicine. Her lab integrates bioengineering and stem cell biology to develop new therapeutic approaches for treating diseases such as cardiovascular disorders and musculoskeletal injuries.
The Liao Laboratory’s research has been centered upon the interrogation of cardiovascular physiology, from the cellular level to the organismal level, to understand the molecular underpinnings of human heart disease.
The Cardiovascular Biomechanics Computation Lab develops fundamental computational methods for studying cardiovascular disease progression, surgical methods, treatment planning, and medical devices.
The Clinical Biomarker and Phenotype Core Laboratory (BPCL) provides state of the art evaluation of cardiovascular phenotypes for clinical and translational studies.
The Liao Laboratory’s research has been centered upon the interrogation of cardiovascular physiology, from the cellular level to the organismal level, to understand the molecular underpinnings of human heart disease.
The Wu Lab studies patient- and disease-specific iPSCs to uncover cardiovascular disease mechanisms, accelerate drug discovery, develop "clinical trial in a dish" models, and advance precision medicine for prevention and treatment.
The Yang Lab focuses on innovation in restoring the failing heart. The Lab combines stem cell derived biologics and novel imaging modalities to advance cardiovascular therapeutics and diagnostics for heart failure. There is a strong focus on translating basic discoveries into clinical reality. The Lab is funded by NIH, AHA, CIRM, and Stanford intramural awards. The findings reported by the Lab is frequently presented at the American Heart Association, American College of Cardiology, International Society of Stem Cell Research, and other national and international meetings.
The Kapiloff lab studies scaffold protein-formed signalosomes, exploring their composition, role in integrating upstream signals to regulate downstream effectors, physiological relevance, and potential as therapeutic targets.
The Karakikes Lab aims to uncover fundamental new insights into the molecular mechanisms and functional consequences of pathogenic mutations associated with familial cardiovascular diseases.
The Liao Laboratory’s research has been centered upon the interrogation of cardiovascular physiology, from the cellular level to the organismal level, to understand the molecular underpinnings of human heart disease.
The Mercola laboratory is focused on developing new therapies for cardiovascular disease. Their research combines in vitro disease models using cardiovascular cells generated from induced pluripotent stem cells (iPSCs) with high throughput screening to define disease mechanisms, identify drug targets and develop drug leads.
The Wu research laboratory seeks to identify mechanisms responsible for human congenital heart disease, the most common cause of still-births in the U.S. and one of the major contributors to morbidity and mortality in infants and toddlers.
CARL is dedicated to improving outcomes for patients with arrhythmias (heart rhythm irregularities), by developing state-of-the-art bioengineering-computational tools, acquiring exquisitely detailed clinical data, then testing solutions prospectively in patients.
The Reddy laboratory aims to understand heart failure mechanisms in congenital heart disease and develop plasma biomarkers for early detection, disease monitoring, and risk stratification.
The de Jesus Perez research group focuses on understanding the genetic, cellular and molecular mechanisms involved in the pathogenesis of pulmonary arterial hypertension (PAH).
The Rabinovitch Lab research program seeks to identify the cellular and molecular programs that are dysregulated in vascular disease with a focus on pulmonary arterial hypertension (PAH).
The Karakikes Lab aims to uncover fundamental new insights into the molecular mechanisms and functional consequences of pathogenic mutations associated with familial cardiovascular diseases.
The Liao Laboratory’s research has been centered upon the interrogation of cardiovascular physiology, from the cellular level to the organismal level, to understand the molecular underpinnings of human heart disease.
The Mercola laboratory is focused on developing new therapies for cardiovascular disease. Their research combines in vitro disease models using cardiovascular cells generated from induced pluripotent stem cells (iPSCs) with high throughput screening to define disease mechanisms, identify drug targets and develop drug leads.
The Wu Lab studies patient- and disease-specific iPSCs to uncover cardiovascular disease mechanisms, accelerate drug discovery, develop "clinical trial in a dish" models, and advance precision medicine for prevention and treatment.
The Wu research laboratory seeks to identify mechanisms responsible for human congenital heart disease, the most common cause of still-births in the U.S. and one of the major contributors to morbidity and mortality in infants and toddlers.
The Yang Lab focuses on innovation in restoring the failing heart. The Lab combines stem cell derived biologics and novel imaging modalities to advance cardiovascular therapeutics and diagnostics for heart failure. There is a strong focus on translating basic discoveries into clinical reality. The Lab is funded by NIH, AHA, CIRM, and Stanford intramural awards. The findings reported by the Lab is frequently presented at the American Heart Association, American College of Cardiology, International Society of Stem Cell Research, and other national and international meetings.
The Leeper laboratory studies the vascular biology of atherosclerosis and aneurysm disease. They are interested in the molecular mechanisms that mediate vascular disease, and developing new translational therapies directed against them.
The Sayed Laboratory is focused on the development of novel technologies that drive innovation in regenerative medicine, disease modeling, and drug testing in vascular biology.
The Tsao Lab investigates the molecular underpinnings of cardiovascular disease, employing a wide range of biochemical, cellular, and physiological techniques to generate fundamental insights, with the goal of improving risk assessment as well as identifying novel therapeutic targets.